NexImmune to Present at the 2021 Cantor Virtual Global Healthcare Conference

Rhea-AI Summary

NexImmune, a clinical-stage biotechnology company (Nasdaq: NEXI), announced that CEO Scott Carmer will present at the 2021 Cantor Virtual Global Healthcare Conference on September 29, 2021, at 2:00 PM ET. The event will be accessible through NexImmune's Investor Relations page, with a replay available for 90 days. NexImmune focuses on immunotherapy leveraging T cells for targeted immune responses, utilizing a proprietary AIM™ nanoparticle technology. The company’s lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 trials for relapsed AML and multiple myeloma, respectively.

GAITHERSBURG, Md., Sept. 27, 2021 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will present at the 2021 Cantor Virtual Global Healthcare Conference Wednesday, September 29, 2021 at 2:00 PM Eastern time.

The webcast will be accessible on the Investor Relations page of NexImmune’s website at Events and Presentations | NexImmune, Inc. A replay of the presentation will be available at the same location for 90 days following the conference.

About NexImmune

NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation (AIM™) nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency and long-term persistence with reduced potential for off-target toxicities.

NexImmune’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to at least 3 prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and in disease areas outside of oncology, including autoimmune disorders and infectious disease.

For more information, visit www.neximmune.com.

Contacts

Investors:
Chad Rubin, SVP Corporate Affairs
NexImmune, Inc.
646.319.3261
crubin@neximmune.com 

FAQ

What is NexImmune presenting at the Cantor Virtual Global Healthcare Conference 2021?

NexImmune will have CEO Scott Carmer presenting on September 29, 2021, at 2:00 PM ET.

How can I access NexImmune's conference presentation?

The presentation will be available on NexImmune's Investor Relations page during the conference.

What are NexImmune's lead programs in clinical trials?

NexImmune's lead programs are NEXI-001 for relapsed AML and NEXI-002 for multiple myeloma, both in Phase 1/2 trials.

What technology does NexImmune utilize for its immunotherapy approach?

NexImmune uses a proprietary AIM™ nanoparticle technology to target and activate T cells.

What therapeutic areas does NexImmune focus on?

NexImmune is developing therapies primarily in oncology, with potential applications in autoimmune disorders and infectious diseases.